

ICPSR 21600

**National Longitudinal Study of
Adolescent to Adult Health (Add
Health), 1994-2008 [Public Use]**

Kathleen Mullan Harris
University of North Carolina-Chapel Hill

J. Richard Udry
University of North Carolina-Chapel Hill

Wave IV: Biomarkers, Lipids Report

Inter-university Consortium for
Political and Social Research
P.O. Box 1248
Ann Arbor, Michigan 48106
www.icpsr.umich.edu

Terms of Use

The terms of use for this study can be found at:
<http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/21600/terms>

Information about Copyrighted Content

Some instruments administered as part of this study may contain in whole or substantially in part contents from copyrighted instruments. Reproductions of the instruments are provided as documentation for the analysis of the data associated with this collection. Restrictions on "fair use" apply to all copyrighted content. More information about the reproduction of copyrighted works by educators and librarians is available from the United States Copyright Office.

NOTICE

WARNING CONCERNING COPYRIGHT RESTRICTIONS

The copyright law of the United States (Title 17, United States Code) governs the making of photocopies or other reproductions of copyrighted material. Under certain conditions specified in the law, libraries and archives are authorized to furnish a photocopy or other reproduction. One of these specified conditions is that the photocopy or reproduction is not to be "used for any purpose other than private study, scholarship, or research." If a user makes a request for, or later uses, a photocopy or reproduction for purposes in excess of "fair use," that user may be liable for copyright infringement.

2013

Add Health Wave IV Documentation

Lipids

Report prepared by

Eric A. Whitsel
Carmen C. Cuthbertson
Joyce W. Tabor
Alan J. Potter
Mark H. Wener
Patric A. Clapshaw
Ley A. Killeya-Jones
Carolyn T. Halpern
Kathleen Mullan Harris

This research was supported by grant P01-HD31921 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, with cooperative funding from 23 other federal agencies and foundations. Further information may be obtained by contacting Add Health at addhealth@unc.edu.

Carolina Population Center
University of North Carolina at Chapel Hill
123 W. Franklin Street, Room 403-C
Chapel Hill, NC 27517-2524



Table of Contents

Section	Page
1. Introduction	2
2. General Overview of Data Collection	2
3. Capillary Whole Blood Collection.....	3
3.1 Rationale	3
3.2 Equipment	3
3.3 Protocol	4
3.3.1 Main Study	4
3.3.2 Pretest Methodological Variations.....	5
4. Measures of Lipids.....	6
4.1 Lipid Panel.....	6
4.1.1 Rationale.....	6
4.1.2 Assay and Internal Quality Control	6
4.1.2.1 Colorimetric Assays	6
4.1.2.1.1 Total Cholesterol	6
4.1.2.1.2 High-Density Lipoprotein Cholesterol	8
4.1.2.1.3 Triglycerides	9
4.1.2.2 Fluorimetric Assays.....	10
4.1.2.2.1 Total Cholesterol	10
4.1.2.2.2 High-Density Lipoprotein Cholesterol	12
4.1.2.2.3 Triglycerides	13
4.1.2.3 Data Cleaning	15
4.1.2.4 Inter-Conversion of Colorimetric and Fluorimetric Assay Results	16
5. External Quality Control	16
5.1 Reliability	16
5.2 Validity	17
6. Constructed Measures	17
6.1 Lipid Deciles	17
6.2 Flags	17
6.3 Low-Density Lipoprotein Cholesterol Decile	18
6.4 Non-High-Density Lipoprotein Cholesterol Decile	18
6.5 Total to High-Density Lipoprotein Cholesterol Ratio Decile.....	18
6.6 Fasting Duration	18
6.7 Fasted for Nine Hours or More.....	19
6.8 Antihyperlipidemic Medication Use.....	19
6.9 Joint Classification of Self-Reported History of Hyperlipidemia and Antihyperlipidemic Medication Use.....	19
7. References.....	20

1. Introduction

During Wave IV, Add Health collected biological specimens from a large, nationally representative sample of young adults. Given the size of the Wave IV sample, its geographic distribution, and in-home setting of the respondent interviews, biological specimen collection involved practical, relatively non-invasive, cost-efficient and innovative methods. These methods included collection of capillary whole blood via finger prick by trained and certified field interviewers, its *in situ* desiccation, then shipment, assay and archival of dried blood spots. The collection of capillary whole blood followed the collection of cardiovascular and anthropometric measures (Entzel et al. 2009) and saliva (Smolen et al. 2013). It preceded the collection of data on respondent use of prescription and select over-the-counter medications (Tabor et al. 2010). Further details on the design of Add Health Waves I-IV, are available elsewhere (Harris 2012; Harris et al. in press).

Included in the Add Health Wave IV restricted use and public use data are thirteen constructed measures designed to facilitate analysis and interpretation of lipids results:

- Total cholesterol decile
- High-density lipoprotein cholesterol decile
- Triglycerides decile
- Total cholesterol measurement method
- High-density lipoprotein cholesterol measurement method
- Triglycerides measurement method
- Low-density lipoprotein cholesterol decile
- Non-high-density lipoprotein cholesterol decile
- Total to high-density lipoprotein cholesterol ratio decile
- Fasting duration
- Fasted for nine hours or more
- Antihyperlipidemic medication use
- Hyperlipidemia

This document summarizes the rationale, equipment, protocol, assay, internal quality control, data cleaning, external quality control, and classification procedures for each measure listed above. Measures of glucose homeostasis, inflammation, immune function, and candidate genes are documented elsewhere (Whitsel et al. 2012a, 2012b; Smolen et al. 2013).

2. General Overview of Data Collection

A Blaise computer-assisted interview (CAI) program guided trained and certified field interviewers (FIs) through the blood spot collection process. Help screens with step-by-step measurement instructions were accessible within the program. Each FI also carried a Job Aids

Booklet that served as a quick reference guide to study protocols.

Respondents were free to decline any or all measurements and specimen collections while participating in other components of the interview. In the Wave IV data set, any measures that are missing due to unique interview circumstances at correctional facilities are coded as legitimate skips.


Some measurement protocols were revised in the period between the Wave IV Pretest (conducted in 2007) and the Main Study (conducted in 2008). Where the Pretest and Main Study data collection protocols differed significantly, this report documents the key differences between them. Pretest cases in the Wave IV data set are flagged for identification.

3. Capillary Whole Blood Collection

3.1 Rationale

Capillary whole blood was collected to provide Add Health with the biological specimens necessary to assay and interpret a pre-specified panel of metabolic, hematologic, inflammatory, and immune biomarkers, including the lipid panel described below. It also was collected to establish a dried capillary whole blood spot archive capable of supporting future assays and ancillary studies.

Exhibit 1. Capillary whole blood collection equipment



3.2 Equipment

Equipment included sterile lancets, a rubber strap, alcohol prep pads, gauze, Band-Aid type adhesive dressings, gloves, a biohazard container, a Chux-type absorbent underpad, and a seven-spot capillary whole blood collection card (Whatman 903® *Protein Saver*, Whatman Inc., Piscataway, NJ) to which a stabilizing, buffered preservative had been pre-applied to Spot #1 (Exhibit 1).

3.3 Protocol

3.3.1 Main Study

During the preceding anthropometric data collection procedure, all female respondents were asked specifically whether they had a prior mastectomy and, if so, on which side. If there were contraindications to using the right hand for capillary whole blood collection, the left hand was used. If there were contraindications on both hands, capillary whole blood was not collected.

FIs collected capillary whole blood from the respondent's middle or ring finger, unless one of the following contraindications was present:

- open sores, wounds, gauze dressings or rashes;
- casts, splints or shunts;
- intravenous (IV) catheters or other attached medical devices;
- swelling, withering or paralysis; or
- finger on same side as prior mastectomy.

FIs prepared the work surface for capillary whole blood collection and donned gloves. The help screen on the computer laptop directed FIs to refer to the Job Aids Booklet for the Fainting Protocol. FIs selected a finger for the procedure, cleaned it with the alcohol prep pad, and let it fully dry. While the finger was drying, FIs asked respondents to hang the selected finger below their waist while applying the rubber strap to the midpoint of the upper, ipsilateral arm. After placing the rubber strap, FIs started a timer on the laptop computer designed to sound an audible cue after three minutes to prompt removal of the rubber strap. FIs placed the clean finger against the work surface and firmly placed a sterile lancet against it to prick the fingertip, slightly lateral of center. FIs firmly wiped away the first drop of capillary whole blood with gauze, applying pressure to the base of (but not milking) the finger to facilitate flow. FIs were trained to allow a large droplet to accumulate before dropping it onto the first circle of the seven-spot capillary whole blood collection card and to do the same for the remaining six circles from left to right, all without allowing the fingertip to touch the card (Exhibit 2).

Exhibit 2. Collecting the capillary whole blood.



When seven capillary whole blood spots were successfully collected (or blood droplet formation ceased), FIs wiped off remaining blood with gauze, instructed respondents to firmly apply the gauze to the finger for at least two minutes, and then applied an adhesive dressing to it. FIs collecting fewer than five spots less than 80% full from a single prick requested respondents' permission to repeat the capillary whole blood collection procedure on a second finger from the contralateral hand. FIs asked respondents to discard used capillary whole blood collection equipment in their own trash receptacle (except for lancets which were discarded in the biohazard container). FIs discarded them in the biohazard container when interviews were conducted in public locations.

FIs bar code labeled each capillary whole blood spot collection card with the corresponding respondent biospecimen ID and then air dried it for three hours. Thereafter, FIs packaged each card with a desiccant pack and shipped it in a FedEx Priority Overnight envelope to the University of Washington Department of Laboratory Medicine (UW Lab Med, Mark H. Wener, M.D., Director, Seattle, WA) for assay.

UW Lab Med received the FedEx Priority Overnight envelopes containing a single dried blood spot collection card and desiccant pack. They scanned the FedEx tracking number and bar code-labeled card into a database in the order of receipt. They also keyed the receipt date, number of dried blood spots per card (0-7), number of adequate blood spots per card defined by blood filling $\geq 80\%$ of the target area (0-7), comments on dried blood spot quality, and condition of the desiccant pack alongside the biospecimen ID. They grouped the cards (≤ 25 per group), sealed the groups in Ziploc bags with desiccant packs, and stored them at -70°C until processing. Immediately before processing, they warmed cards to room temperature (23°C) and re-scanned the bar code-labeled card into the database. The cards were punched for all assays except hemoglobin A_{1c} (HbA_{1c}), returned to the freezers, then shipped frozen to the Carolina Population Center (CPC, University of North Carolina, Chapel Hill, NC) for permanent archival. At the CPC, Spot #1 on each card was removed, re-bundled (≤ 25 per group), sealed in plastic bags with desiccant, and shipped frozen by next day air to FlexSite Diagnostics, Inc. (Robert A. Ray, Ph.D., Director, Palm City, FL) for HbA_{1c} assay (see Whitsel et al. 2012a for documentation of measures of glucose homeostasis).

3.3.2 Pretest Methodological Variations

During the Pretest, respondents chose the middle or ring finger and FIs were directed not to use the thumb, index finger or fifth digit/little finger for capillary whole blood collection. FIs also collected up to ten capillary whole blood spots: three on a BIOSAFE Blood Collection Card for HbA_{1c} and Cholesterol Panel (BIOSAFE Laboratories, Inc., Chicago, IL) and seven more on a Whatman 903® Protein Saver, (Whatman Inc., Piscataway, NJ). The BIOSAFE card was made of Whatman 903® filter paper (Whatman International, Dassel, Germany) with a top layer of TELFA (Kendall Healthcare Products, Mansfield, MA) to minimize the effects of blood spot layering and inadvertent touching of cards with respondent fingertips (Bui et al. 2002a, 2002b; Grzeda et al. 2002; Maggiore, 2002; Tyrrell, 1999). A stabilizing borate buffered preservative was pre-applied by BIOSAFE to the area of the BIOSAFE card designated for HbA_{1c} assay and dried. As in the main study, the Whatman 903® Protein Saver card was shipped to UW Lab Med for the Pretest and Main Study lipid assays.

4. Measures of Lipids

4.1 Lipid Panel

4.1.1 Rationale

Cholesterol and triglyceride are lipids that travel through the blood in protein-containing particles called lipoproteins. The particles include low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and other relatively triglyceride (TG)-rich lipoproteins. Their concentrations are associated with cardiovascular disease risk (Cui et al. 2001; Klag et al. 1993; Srinivasan et al. 2006; Stamler et al. 2000) and are targets of antihyperlipidemic therapy (National Cholesterol Education Panel 2002). Total cholesterol (TC), HDL-C, and TG were therefore assayed in dried capillary whole blood spots.

4.1.2 Assays and Internal Quality Control

4.1.2.1 Colorimetric Assays

As described below, the three lipids were initially assayed using colorimetric procedures that measure change in color (optical density) reflective of increases in plasma lipid concentrations.

4.1.2.1.1 Total Cholesterol

The dried blood spot (DBS) total cholesterol colorimetric assay involves a series of coupled enzymatic reactions. A punch from a DBS card containing a total cholesterol (TC) assay calibrator, quality control (QC) sample or respondent sample is eluted with a buffer solution. The

elution solution is incubated with assay reagent containing cholesterol ester hydrolase, cholesterol oxidase, peroxidase, and a chromogen. The cholesterol ester hydrolase catalyzes the conversion of cholesterol esters to cholesterol, and this and de novo cholesterol is oxidized by cholesterol oxidase, producing hydrogen peroxide (H_2O_2) as a byproduct. In the presence of peroxidase, the H_2O_2 reacts with the chromogen causing the solution to develop color. The TC concentration is directly proportional to the absorbance of the solution; absorbance is measured spectrophotometrically. A standard curve is constructed by plotting the absorbance values of the calibrators against the known TC concentrations. Using the standard curve, the absorbance values of the QC samples and patient samples are read as TC concentrations. Acceptability of the assay is determined by comparing the TC concentrations of the QC samples with their established values.

DBS TC assay calibrators were constructed from high TC concentration pooled human plasma (University of Washington Department of Laboratory Medicine, Seattle, WA; UW Lab Med) serially diluted with 7% bovine serum albumin in phosphate buffered saline (BSA/PBS; Sigma Aldrich, St. Louis, MO) to the desired final TC concentration. Two DBS QC samples were constructed from a separate pool of human plasma, either undiluted (high TC concentration QC sample) or diluted with BSA/PBS (low TC concentration QC sample). Each calibrator and QC sample solution was mixed with a constant volume of washed human erythrocytes (UW Lab Med), pipetted in 75 μ l aliquots onto No. 903 filter paper (Whatman, Piscataway, NJ) and dried for 4hr at room temperature (23°C). The final TC concentration of each calibrator and QC sample solution was determined by analysis on a UniCel Dx C 800 Synchron Clinical System (Beckman Coulter, Miami, FL). DBS calibrators, QC samples and study samples were sealed in Ziploc bags with desiccant packs and stored at -70°C until processing. Immediately prior to processing, DBS were warmed to room temperature and then a single 3.2mm (1/8in) diameter punch was punched from each DBS card into a microtiter plate well (Greiner Bio-One, Monroe, North Carolina). Microtiter plates were either immediately assayed or were firmly sealed and stored at -70°C pending assay.

Immediately prior to assay, microtiter plates were warmed to room temperature. 75 μ l Cholesterol Assay Elution Buffer (Synermed, Westfield, IN) was added to each microtiter plate well. The plate was sealed and gently shaken overnight on a microplate shaker (Delfia Plateshake, PerkinElmer, Waltham, MA). 275 μ l Cholesterol Assay Reagent (Synermed) was added to each well, the plate gently shaken for 30sec and then incubated for 30min at 37°. 20 μ l Cholesterol Assay Precipitation Buffer (Synermed) was added to each well, the plate gently shaken for 30sec and then centrifuged for 10min at 2300rpm to pellet particulates. 200 μ l of the solution was removed from each well without disturbing the pellet and transferred to an assay microtiter plate. The plate was gently shaken for 30sec and the absorbance (optical density) of each well was read at 630nm by a microtiter plate reader (Synergy HT, BioTek, Winooski, VT). A linear regression calibration curve, constructed by plotting the assigned concentrations of the

calibrators against the recorded absorbance values, was used to convert the OD value of each sample into a DBS TC concentration (Gen5 Software, BioTek).

The TC assay lower limit of detection was 21mg/dl, within-assay imprecision (CV) was 10.9% and between-assay imprecision was 14.4%. The correlation between the TC concentrations of 112 DBS samples analyzed by the DBS assay and the TC concentrations of paired plasma samples was improved by adjusting the DBS TC value by the DBS sample hemoglobin absorbance per the empiric formula DBS TC value $\times (1 + [\text{sample hemoglobin absorbance} - \text{mean sample hemoglobin absorbance}])$. The linear relationship (Pearson $R = 0.93$) was Plasma TC value = (hemoglobin absorbance-adjusted DBS TC value – 36.051) / 1.472.

4.1.2.1.2 High-Density Lipoprotein Cholesterol

The dried blood spot (DBS) HDL cholesterol colorimetric assay involves a series of coupled enzymatic reactions. A punch from a DBS card containing a HDL cholesterol (HDL-C) assay calibrator, quality control (QC) sample or respondent sample is eluted with a buffer solution. The elution solution is mixed with a reagent containing a chromogen and anti-human β -lipoprotein antibody to bind non-HDL lipoproteins into nonreactive complexes. A second reagent, containing cholesterol ester hydrolase, cholesterol oxidase and peroxidase, is then added. The cholesterol ester hydrolase catalyzes the conversion of HDL-C into cholesterol, which is in turn oxidized by cholesterol oxidase and produces hydrogen peroxide (H_2O_2) as a byproduct. In the presence of peroxidase, H_2O_2 reacts with the chromogen causing the solution to develop color. The HDL-C concentration is directly proportional to the absorbance of the solution; absorbance is measured spectrophotometrically. A standard curve is constructed by plotting the absorbance values of the calibrators against the known HDL-C concentrations. Using the standard curve, the absorbance values of the QC samples and patient samples are read as HDL-C concentrations. Acceptability of the assay is determined by comparing the HDL-C concentrations of the QC samples with their established values.

DBS HDL-C assay calibrators were constructed from high HDL-C concentration pooled human plasma (University of Washington Department of Laboratory Medicine, Seattle, WA; UW Lab Med) serially diluted with 7% bovine serum albumin in phosphate buffered saline (BSA/PBS; Sigma Aldrich, St. Louis, MO) to the desired final HDL-C concentration. Two DBS QC samples were constructed from a separate pool of human plasma, either undiluted (high HDL-C concentration QC sample) or diluted with BSA/PBS (low HDL-C concentration QC sample). Each calibrator and QC sample solution was mixed with a constant volume of washed human erythrocytes (UW Lab Med), pipetted in 75 μ l aliquots onto No. 903 filter paper (Whatman, Piscataway, NJ) and dried for 4hr at room temperature (23°C). The final HDL-C concentration of each calibrator and QC sample solution was determined by analysis on a UniCel Dx C 800 Synchron Clinical System (Beckman Coulter, Miami, FL). DBS calibrators, QC samples and

study samples were sealed in Ziploc bags with desiccant packs and stored at -70°C until processing. Immediately prior to processing, DBS were warmed to room temperature and then three 3.2mm (1/8in) diameter punches were punched from each DBS card into a microtiter plate well (Greiner Bio-One, Monroe, North Carolina). Microtiter plates were either immediately assayed or were firmly sealed and stored at -70°C pending assay.

Immediately prior to assay, microtiter plates were warmed to room temperature. 75µl Cholesterol Assay Elution Buffer (Synermed, Westfield, IN) was added to each microtiter plate well. The plate was sealed and gently shaken overnight on a microplate shaker (Delfia Plateshake, PerkinElmer, Waltham, MA). 200µl of EZ HDL Cholesterol Reagent 1 (Trinity Biotech, St Louis, MO) was added, the plate gently shaken for 30sec and then incubated at 37°C for 45min. At the conclusion of this incubation, 60µl of EZ HDL Cholesterol Reagent 2 (Trinity Biotech) was added, the assay plate shaken for 30sec and then incubated at 37°C for 30min. 17µl HDL Cholesterol Precipitation Buffer was added to each well, the plate gently shaken for 30sec and then centrifuged for 10min at 2300rpm to pellet particulates. 200µl of the solution was removed from each well without disturbing the pellet and transferred to an assay microtiter plate. The plate was gently shaken for 30sec and the absorbance (optical density) of each well was read at 590nm by a microtiter plate reader (Synergy HT, BioTek, Winooski, VT). A linear regression calibration curve, constructed by plotting the assigned concentrations of the calibrators against the recorded absorbance values, was used to convert the OD value of each sample into a DBS HDL-C concentration (Gen5 Software, BioTek).

The HDL-C assay lower limit of detection was 9mg/dl, within-assay imprecision (CV) was 5.8% and between-assay imprecision was 5.9%. The correlation between the HDL-C concentrations of 112 DBS samples analyzed by the DBS assay and the HDL-C concentrations of paired plasma samples was improved by adjusting the DBS HDL-C value by the DBS sample hemoglobin absorbance per the empiric formula $\text{DBS HDL-C value} \times (\text{sample hemoglobin absorbance} / \text{mean sample hemoglobin absorbance})$. The linear relationship (Pearson $R = 0.91$) was $\text{Plasma HDL-C} = (\text{hemoglobin absorbance-adjusted DBS HDL-C value} + 0.089) / 1.344$.

4.1.2.1.3 Triglycerides

The dried blood spot (DBS) triglycerides colorimetric assay involves a series of coupled enzymatic reactions. Punches from a DBS card containing a triglycerides (TG) assay calibrator, quality control (QC) sample or respondent sample are eluted with a buffer solution. TG in the elution solution is hydrolyzed by lipase to produce glycerol, the glycerol is phosphorylated by glycerol kinase to produce glycerol-3-phosphate which, in turn, is oxidized by glycerophosphate oxidase producing hydrogen peroxide (H_2O_2) as a byproduct. In the presence of peroxidase, the H_2O_2 reacts with a chromogen causing the solution to develop color. The TG concentration is directly proportional to the absorbance of the solution, measured by spectrophotometry. A standard curve is constructed by plotting the absorbance values of the calibrators against their

known TG concentrations. Using the standard curve, the absorbance values of the QC samples and patient samples are read as TG concentrations. Acceptability of the assay is determined by comparing the TG concentrations of the QC samples with their established values.

DBS TG assay calibrators were constructed from high TG concentration pooled human plasma (University of Washington Department of Laboratory Medicine, Seattle, WA; UW Lab Med) serially diluted with 7% bovine serum albumin in phosphate buffered saline (BSA/PBS; Sigma Aldrich, St. Louis, MO) to the desired final TG concentration. Two DBS QC samples were constructed from a separate pool of human plasma, either undiluted (high TG concentration QC sample) or diluted with BSA/PBS (low TG concentration QC sample). The final TG concentration of each calibrator and QC sample solution was determined by analysis on a UniCel DxC 800 Synchron Clinical System (Beckman Coulter, Miami, FL). Each calibrator and QC sample solution was mixed with a constant volume of washed human erythrocytes (UW Lab Med), pipetted in 75µl aliquots onto No. 903 filter paper (Whatman, Piscataway, NJ) and dried for 4hr at room temperature (23°C). DBS calibrators, QC samples and study samples were sealed in Ziploc bags with desiccant packs and stored at -70°C until processing. Immediately prior to processing, DBS cards were warmed to room temperature and then two 3.2mm (1/8in) diameter punches were punched from each DBS card into a microtiter plate well (Greiner Bio-One, Monroe, North Carolina). Microtiter plates were either immediately assayed or were firmly sealed and stored at -70°C pending assay.

Immediately prior to assay, microtiter plates were warmed to room temperature. 75µl of 100% methanol (Sigma Aldrich, St. Louis, MO) was added to each microtiter plate well. The plate was sealed and gently shaken for 3hr at room temperature on a microplate shaker (Delfia Plateshake, PerkinElmer, Waltham, MA). 275µL Triglycerides Assay Reagent (Beckman Coulter, Brea, CA) was added to each well, the plate gently shaken for 30sec and then incubated for 30min at 37°. 200 µl of the reaction mixture was transferred from each well of the elution plate to a second microtiter plate. The plate was gently shaken for 30sec and the absorbance (optical density) of each well was read at 515nm by a microtiter plate reader (Synergy HT, BioTek, Winooski, VT). A linear regression calibration curve, constructed by plotting the assigned concentrations of the calibrators against the recorded absorbance values, was used to convert the OD value of each sample into a DBS TG concentration (Gen5 Software, BioTek).

The TG assay lower limit of detection was less than 20mg/dl, within-assay imprecision (CV) was 7.1% and between-assay imprecision was 8.9%. The TG concentrations of 112 DBS samples analyzed by the DBS assay correlated with the TG concentrations of paired plasma samples analyzed by the DxC 800 (Pearson R = 0.97) and were linearly related ($\text{Plasma TG} = [\text{DBS TG value} - 1.6] / 1.25$).

4.1.2.2 Fluorimetric Assays

During the course of field work, colorimetric methods were replaced with fluorimetric alternatives, described below. The anticipated advantages of the fluorimetric methods—which involve ultraviolet excitation of and spectroscopic measurement of light emitted from fluorochromes—led to their adoption. Overall, 13905, 13676, and 13596 respondents had either a colorimetric or fluorimetric concentration of TC, HDL-C, and TG, respectively. Of these respondents, 95%, 82% and 63% had a colorimetric concentration, while 46%, 47%, and 47% had a fluorimetric concentration of the respective measures. Inter-conversion of colorimetric and fluorimetric concentrations is described below (Section 4.1.2.4).

4.1.2.2.1 Total Cholesterol

The dried blood spot (DBS) total cholesterol fluorimetric assay involves a series of coupled enzymatic reactions. A punch from a DBS card containing a total cholesterol (TC) assay calibrator, quality control (QC) sample or respondent sample is eluted with a buffer solution. The elution solution is incubated with assay reagent containing cholesterol ester hydrolase, cholesterol oxidase, peroxidase, and a fluorogen. The cholesterol ester hydrolase catalyzes the conversion of cholesterol esters to cholesterol, and this and de novo cholesterol is oxidized by cholesterol oxidase, producing hydrogen peroxide (H_2O_2) as a byproduct. In the presence of peroxidase, the H_2O_2 reacts with the non-fluorescent fluorogen to produce a fluorescent fluorophore. The TC concentration is directly proportional to the fluorescent intensity of the solution; fluorescence is measured spectrophotometrically. A standard curve is constructed by plotting the fluorescence values of the calibrators against the known TC concentrations. Using the standard curve, the fluorescence values of the QC samples and patient samples are read as TC concentrations. Acceptability of the assay is determined by comparing the TC concentrations of the QC samples with their established values.

DBS TC assay calibrators were constructed from high TC concentration pooled human plasma (University of Washington Department of Laboratory Medicine, Seattle, WA; UW Lab Med) serially diluted with 7% bovine serum albumin in phosphate buffered saline (BSA/PBS; Sigma Aldrich, St. Louis, MO) to the desired final TC concentration. Two DBS QC samples were constructed from a separate pool of human plasma, either undiluted (high TC concentration QC sample) or diluted with BSA/PBS (low TC concentration QC sample). Each calibrator and QC sample solution was mixed with a constant volume of washed human erythrocytes (UW Lab Med), pipetted in 75 μ l aliquots onto No. 903 filter paper (Whatman, Piscataway, NJ) and dried for 4hr at room temperature (23°C). The final TC concentration of each calibrator and QC sample solution was determined by analysis on a UniCel DxC 800 Synchron Clinical System (Beckman Coulter, Miami, FL). DBS calibrators, QC samples and study samples were sealed in Ziploc bags with desiccant packs and stored at -70°C until processing. Immediately prior to processing, DBS

were warmed to room temperature and then a single 3.2mm (1/8in) diameter punch was punched from each DBS card into a microtiter plate well (Greiner Bio-One, Monroe, North Carolina). Microtiter plates were either immediately assayed or were firmly sealed and stored at -70°C pending assay.

Immediately prior to assay, microtiter plates were warmed to room temperature. A TC elution buffer comprised of 400µl ddH₂O with 0.1% Triton X-100 (Sigma) was added to each microtiter plate well. The plate was sealed and gently shaken for 1hr on a microplate shaker (Delfia Plateshake, PerkinElmer, Waltham, MA). 20µl of eluent was transferred from each well of the elution plate to an assay microtiter plate. This was followed by addition of 100µl of TC assay reagent comprised of 70% Cholesterol Chromogen (Synermed, Westfield, IN), 29% Cholesterol Enzyme (Synermed) and 1% Cayman ADHP (10-acetyl-3,7-dihydroxyphenoxazine; Cayman Chemical, Ann Arbor, MI). The plate was gently shaken for 30sec and then incubated at 37°C for 30min. The fluorescence intensity (RFU) of each well was read at 530/25nm excitation and 590/35nm emission by a microtiter plate reader (Synergy HT, BioTek, Winooski, VT). A linear regression calibration curve, constructed by plotting the assigned concentrations of the calibrators against the recorded fluorescence values, was used to convert the RFU value of each sample into a DBS TC concentration (Gen5 Software, BioTek).

The TC assay lower limit of detection was 27mg/dl, within-assay imprecision (CV) was 4.0% and between-assay imprecision was 4.7%. The TC concentrations of 105 DBS samples analyzed by the DBS assay correlated with the TC concentrations of paired plasma samples (Pearson R = 0.93) and were linearly related ($\text{Plasma TC} = [\text{DBS TC} - 17.141] / 1.582$). Correction for hematocrit did not improve the agreement between the serum and DBS TC values.

4.1.2.2.2 High-Density Lipoprotein Cholesterol

The dried blood spot (DBS) HDL cholesterol fluorimetric assay involves a series of coupled enzymatic reactions. A punch from a DBS card containing an HDL cholesterol (HDL-C) assay calibrator, quality control (QC) sample or respondent sample is eluted with deionized water. The elution solution is mixed with a reagent containing anti-human β-lipoprotein antibody (to bind non-HDL lipoproteins into nonreactive complexes) and a fluoren. A second reagent, containing cholesterol ester hydrolase, cholesterol oxidase and peroxidase, is then added. The cholesterol ester hydrolase catalyzes the conversion of HDL-C into cholesterol, which is in turn oxidized by cholesterol oxidase and produces hydrogen peroxide (H₂O₂) as a byproduct. In the presence of peroxidase, H₂O₂ reacts with the non-fluorescent fluoren to produce a fluorescent fluorophore. The HDL-C concentration is directly proportional to the fluorescent intensity of the solution; fluorescence is measured spectrophotometrically. A standard curve is constructed by plotting the fluorescence values of the calibrators against the known HDL-C concentrations. Using the standard curve, the fluorescence values of the QC samples and patient samples are read as HDL-

C concentrations. Acceptability of the assay is determined by comparing the HDL-C concentrations of the QC samples with their established values.

DBS HDL-C assay calibrators were constructed from high HDL-C concentration pooled human plasma (University of Washington Department of Laboratory Medicine, Seattle, WA; UW Lab Med) serially diluted with 7% bovine serum albumin in phosphate buffered saline (BSA/PBS; Sigma Aldrich, St. Louis, MO) to the desired final HDL-C concentration. Two DBS QC samples were constructed from a separate pool of human plasma, either undiluted (high HDL-C concentration QC sample) or diluted with BSA/PBS (low HDL-C concentration QC sample). Each calibrator and QC sample solution was mixed with a constant volume of washed human erythrocytes (UW Lab Med), pipetted in 75µl aliquots onto No. 903 filter paper (Whatman, Piscataway, NJ) and dried for 4hr at room temperature (23°C). The final HDL-C concentration of each calibrator and QC sample solution was determined by analysis on a UniCel Dx C 800 Synchron Clinical System (Beckman Coulter, Miami, FL). DBS calibrators, QC samples and study samples were sealed in Ziploc bags with desiccant packs and stored at -70°C until processing. Immediately prior to processing, DBS were warmed to room temperature and then a single 3.2mm (1/8in) diameter punch was punched from each DBS card into a microtiter plate well (Greiner Bio-One, Monroe, North Carolina). Microtiter plates were either immediately assayed or were firmly sealed and stored at -70°C pending assay.

Immediately prior to assay, microtiter plates were warmed to room temperature. 400µl diH₂O HDL-C elution buffer was added to each microtiter plate well. The plate was sealed and gently shaken for 1hr on a microplate shaker (Delfia Plateshake, PerkinElmer, Waltham, MA). 40µl of eluent was transferred from each well of the elution plate to an assay microtiter plate. This was followed by addition of 75µl of HDL-C assay reagent 1 comprised of 99% EZ HDL Cholesterol Reagent 1 (Trinity Biotech, St Louis, MO) and 1% Cayman ADHP (10-acetyl-3,7-dihydroxyphenoxazine; Cayman Chemical, Ann Arbor, MI). The plate was gently shaken for 30sec and then incubated at 37°C for 25min. At the conclusion of this incubation, 25µl of HDL-C assay reagent 2 (EZ HDL Cholesterol Reagent 2; Trinity Biotech) was added, the assay plate shaken for 30sec and then incubated at 37°C for 30min. The fluorescence intensity (RFU) of each well was read at 530/25nm excitation and 590/35nm emission by a Synergy HT Microtiter Plate Reader (BioTek, Winooski, VT). A linear regression calibration curve, constructed by plotting the assigned concentrations of the calibrators against the recorded fluorescence values, was used to convert the RFU value of each sample into a DBS HDL-C concentration (Gen5 Software, BioTek).

The HDL-C assay lower limit of detection was 15mg/dl, within-assay imprecision (CV) was 5.3% and between-assay imprecision was 9.9%. The HDL-C concentrations of 104 DBS samples analyzed by the DBS assay correlated with the HDL-C concentrations of paired plasma samples (Pearson R = 0.88) and were linearly related ($\text{Plasma HDL-C} = [\text{DBS HDL-C} - 32.941] / 0.965$).

Correction for hematocrit did not improve the agreement between the serum and DBS HDL-C values.

4.1.2.2.3 Triglycerides

The dried blood spot (DBS) triglycerides (TG) fluorimetric assay involves a series of coupled enzymatic reactions. A punch from a DBS card containing a TG assay calibrator, quality control (QC) sample or respondent sample is eluted with a buffer solution. TG in the elution solution is hydrolyzed by lipase to produce glycerol, the glycerol is phosphorylated by glycerol kinase to produce glycerol-3-phosphate which, in turn, is oxidized by glycerophosphate oxidase producing hydrogen peroxide (H_2O_2) as a byproduct. In the presence of peroxidase, the H_2O_2 reacts with a non-fluorescent fluorogen, converting it into a fluorescent fluorophore. The TG concentration is directly proportional to the fluorescence intensity of the solution, measured by spectrophotometry. A standard curve is constructed by plotting the fluorescence values of the calibrators against the known TG concentrations. Using the standard curve, the fluorescence values of the QC samples and patient samples are read as TG concentrations. Acceptability of the assay is determined by comparing the TG concentrations of the QC samples with their established values.

DBS TG assay calibrators were constructed from high TG concentration pooled human plasma (University of Washington Department of Laboratory Medicine, Seattle, WA; UW Lab Med) serially diluted with 7% bovine serum albumin in phosphate buffered saline (BSA/PBS; Sigma Aldrich, St. Louis, MO) to the desired final TG concentration. Two DBS QC samples were constructed from a separate pool of human plasma, either undiluted (high TG concentration QC sample) or diluted with BSA/PBS (low TG concentration QC sample). Each calibrator and QC sample solution was mixed with a constant volume of washed human erythrocytes (UW Lab Med), pipetted in 75 μ l aliquots onto No. 903 filter paper (Whatman, Piscataway, NJ) and dried for 4hr at room temperature (23 $^{\circ}$ C). The final TG concentration of each solution used to create a DBS calibrator or QC sample was determined by analysis on a UniCel Dx C 800 Synchron Clinical System (Beckman Coulter, Miami, FL). DBS calibrators, QC samples and study samples (created from approximately five single 50 μ l drops of whole blood obtained from a finger-stick placed separately on Protein Saver Card No. 903 filter paper (Whatman) and dried at room temperature) were sealed in Ziploc bags with desiccant packs and stored at -70 $^{\circ}$ C (Thermo Scientific Revco Ultima Plus, Fisher Scientific, Pittsburg, PA) until processing. Immediately prior to processing, DBS were warmed to room temperature and then a single 3.2mm (1/8in) diameter punch was punched from each DBS card using a BSD700 Semi-Automated Dried Sample Puncher (BSD Robotics, Brisbane, QLD, Australia) into a deep-well microtiter plate well (Greiner Bio-One, Monroe, NC). Microtiter plates were either immediately assayed or were firmly sealed (CapMat, Greiner Bio-One) and stored at -70 $^{\circ}$ C pending assay.


Immediately prior to assay, microtiter plates were warmed to room temperature. A TG elution buffer comprised of 400µl ddH₂O with 0.1% Triton X-100 (Sigma) was added to each microtiter plate well. The plate was sealed and vigorously shaken for 1hr on a microplate shaker (Delfia Plateshake, PerkinElmer, Waltham, MA). 40 µl of eluent was transferred from each well of the elution plate to a shallow-well assay microtiter plate (Greiner Bio-One). This was followed by addition of 100µl of eluent was transferred from each well of the elutiChromogen Reagent (Beckman, Brea, CA), 5% Triglycerides Enzyme Reagent (Beckman) and 1% Cayman ADHP (10-acetyl-3,7-dihydroxyphenoxazine; Cayman Chemical, Ann Arbor, MI). The plate was gently shaken for 30sec and then incubated at 37°C for 30min (Lindberg/Blue M, Asheville, NC). The fluorescence intensity (RFU) of each well was read at 530/25nm excitation and 590/35nm emission by a microtiter plate reader (Synergy HT, BioTek, Winooski, VT). A linear regression calibration curve, constructed by plotting the assigned concentrations of the calibrators against the recorded fluorescence values, was used to convert the RFU value of each sample into a DBS TG concentration (Gen5 Software, BioTek). An assay would be rejected if the mean value of a control sample was greater than 3SD above or below the established mean value, or if the mean value of each control sample was greater than 2SD above or below the respective established mean value.

The TG assay lower limit of detection was 20mg/dl, within-assay imprecision was 7.6%CV and between-assay imprecision was 9.4%CV. The TG concentrations of 106 DBS samples analyzed by the DBS assay correlated with the TG concentrations of paired plasma samples (Pearson R = 0.98) and were linearly related ($\text{Plasma TG} = [\text{DBS TG} + 10.3] / 1.438$).

4.1.2.3 Data Cleaning

Plate-specific, linear regression calibration formulae were used to verify laboratory conversion of optical density to lipid concentrations (mg/dl). Seasonal variation was examined by plotting dried blood spot and quality control lipid concentrations (mg/dl) versus receipt date (2007-2009) on a single calendar time scale (1-366 days). Relatively conspicuous patterns of seasonal variation were observed in colorimetric and fluorimetric TC and HDL-C concentrations (e.g. Exhibit 3). They were therefore modeled as a function of time, represented by four seasonal terms: $\sin(2\pi jt/366)$ and $\cos(2\pi jt/366)$, where harmonic $j = (1, 2)$ and time $t = (1, 2, 3, \dots, 366)$. These non-linear models were adjusted for age (yr), sex (male; female), and race/ethnicity (non-Hispanic white; non-Hispanic black; non-Hispanic Asian/Pacific Islander; Mexican; other Hispanic/Latino; other race/multiracial). Goodness of fit as measured by the Akaike information criterion was greatest for these models when compared to a variety of non-linear and linear alternatives. The age-, sex- and race/ethnicity-adjusted harmonic terms estimated in the former model were subtracted from the assayed concentrations of TC and HDL-C (mg/dl). Subtraction had little effect on the overall distribution, mean, or variance of TC and HDL-C, but attenuated the observed seasonal variation (e.g. Exhibit 3).


Exhibit 3. Mean colorimetric TC and HDL-C concentrations, before and after decycling assay results



4.1.2.4 Inter-Conversion of Colorimetric and Fluorimetric Assay Results

Four respondents were randomly selected from each of 24 Add Health Wave IV Main Study strata defined by race / ethnicity (non-Hispanic white; non-Hispanic black; Hispanic; other), sex (male; female) and TG tertile (low, medium, high). Collectively, the stratified, random sample included $4 \times 24 = 96$ respondents whose dried capillary whole blood spot collection cards were submitted for colorimetric and fluorimetric assays by laboratory staff masked to respondent identity. The associations between paired colorimetric and fluorimetric concentrations were modeled using Deming regression (Cornbleet et al. 1979; Deal et al. 2011), i.e. colorimetric concentration = $\alpha + \beta \times$ fluorimetric concentration. Compared to estimates of α (95% confidence interval), β (95% confidence interval), and the Pearson correlation coefficient in the stratified random sample, estimates in much larger convenience samples of overlapping concentrations were comparable, but more precise: 0.66 (0.25, 1.08), 0.95 (0.86, 1.04) and 0.47 for log TC in 5,805 respondents; -24.12 (-31.10, -17.15), 1.34 (1.27, 1.40) and 0.92 for TG in 1,288 respondents; and 17.05 (15.25, 18.85), 0.91 (0.85, 0.97), and 0.55 for HDL-C in 4,040 respondents (Exhibit 4). In the event of missing colorimetric, but non-missing fluorimetric results, the latter values of α and β were therefore used to convert fluorimetric to colorimetric concentrations (See Section 6.2 Flags).

Exhibit 4. Plots of colorimetric versus fluorimetric TC, HDL-C and TG concentrations



5. External Quality Control

5.1 Reliability

Capillary whole blood was collected twice, one to two weeks apart, from a race / ethnicity- and sex-stratified random sample of 100 Add Health respondents, 14% and 17% of whom were fasting ≥ 9 hr at visits 1 and 2. The reliabilities of TC, HDL-C and TG concentrations in this sample were estimated as intra-class correlation coefficients (95% confidence intervals): 0.40 (0.22-0.58), 0.39 (0.21-0.57) and 0.71 (0.60-0.81), respectively. Assuming 95% confidence and a 5% type II error rate, corresponding values of the minimal detectable difference in TC, HDL-C and TG between two, independent samples (each of 1,000 respondents) were 17, 2.7, and 4.1 mg/dl.

5.2 Validity

Three plasma pools, together representing low, medium, and high concentrations of TC, HDL-C and TG were obtained from the Lipid Standardization Program, Centers for Disease Control and Prevention (CDC, Atlanta, GA) and mixed with washed erythrocytes. The plasma-erythrocyte mixture from each pool was used to spot twenty capillary whole blood collection cards. One card per pool was submitted to the laboratory twice per week over a ten-week period for assay of TC, HDL-C and TG by laboratory staff masked to origin of the cards. Mean laboratory – CDC differences in TC, HDL-C and TG concentrations were large: -6, 15, and 30 mg/dl. However, corresponding Pearson correlation coefficients were high: 0.66, 0.73, and 0.85. Moreover, in the Add Health population as a whole, expected among-group differences were observed in HDL-C (male \ll female), TG (fasting \ll non-fasting), and in TC and TG (normal \ll hyperlipidemic respondents) (Table 1).

Table 1. Percent of respondents in the highest lipid decile, by select attributes*

Lipid	Sex		Fasting ≥ 9 hr		Hyperlipidemia [†]	
	Male	Female	Yes	No	Yes	No
TC	10.7	10.1	9.0	10.7	15.6	9.9
HDL-C	6.7	13.5	8.4	10.4	11.0	10.0
TG	14.0	6.6	5.9	11.0	22.2	9.1

*Weighted for unequal sampling probability (n=14,800). [†]Self-reported history or antihyperlipidemic medication use.

6. Constructed Measures

6.1 Lipid Deciles

Variables: TC, HDL and TG

After de-trending, and when necessary, inter-converting assay results, total cholesterol (TC), high-density lipoprotein cholesterol (HDL), and triglyceride (TG) concentrations (mg/dl) were ordered and assigned decile ranks which are reported here. Absolute concentrations (in mg/dl) will remain unavailable given their distinctive reliance on dried capillary whole blood, nascent assay technologies, de-trending, inter-conversion of fluorimetric to colorimetric concentrations, and attendant potential for bias.

6.2 Flags

Variables: TC_FLG, HDL_FLG and TG_FLG

Flags were constructed to identify the method of measuring total cholesterol (TC_FLG), high-density lipoprotein cholesterol (HDL_FLG), and triglycerides (TG_FLG). Flags took the value “*Assayed*” (2) when colorimetrically assayed; “*Imputed*” (1) when converted from fluorimetric assay results; “*Missing*” (.) when blood spots were unavailable, and “*No result*” (9) when assay failed.

6.3 Low-Density Lipoprotein Cholesterol Decile

Variable: LDL

When the triglyceride concentration was < 400 mg/dL, a low-density lipoprotein cholesterol concentration (mg/dl) was indirectly calculated from the concentrations (mg/dl) of total cholesterol, high-density lipoprotein cholesterol and triglycerides, as follows: $LDL-C = TC - HDL-C - [TG \div 5]$ (Friedewald et al. 1972). Concentrations were then ordered and assigned decile ranks.

6.4 Non-High-Density Lipoprotein Cholesterol Decile

Variable: NON_HDL

Although use of the Friedewald equation (Friedewald et al. 1972) is routine, interpretation of indirectly calculated LDL-C is difficult in the presence of post-prandial hypertriglyceridemia. The non-high-density lipoprotein cholesterol concentration (mg/dl) was therefore calculated from the concentrations (mg/dl) of total cholesterol and high-density lipoprotein cholesterol, as follows: $non-HDL-C = TC - HDL-C$. This difference—which is reliable in the non-fasting state (Frost and Havel 1998)—was then ordered and assigned decile ranks.

6.5 Total to High-Density Lipoprotein Cholesterol Ratio Decile

Variable: TC_HDL

Although the ratio of total to high-density lipoprotein cholesterol concentrations (mg/dl) is neither a primary nor secondary target of antihyperlipidemic therapy (National Cholesterol Education Panel, 2002), the ratio has been described as a simple and powerful predictor of cardiovascular disease risk (Castelli et al. 1992; Criqui and Golomb 1998; Hong et al. 1991; Kinosian et al. 1995). It was therefore calculated, as follows: $TC:HDL-C = TC / HDL-C$, then ordered and assigned decile ranks.

6.6 Fasting Duration (hr)

Variable: FASTTIME

In Interview Section 4: General Health and Diet, field interviewers asked respondents the following question: *“At what time did you last eat or drink anything other than water, including sugar-containing candy or gum?”* The response to the question was recorded in hours and minutes and designated AM or PM. On-screen instructions of “12 MIDNIGHT IS AM. 12 NOON IS PM” were provided to the field interviewer for clarification. To calculate fasting times, responses to the above question were subtracted from the laptop time stamp at the start of the interview. Since laptop clocks were set to Eastern Time for field work processing, the CPC Spatial Analysis Unit corrected interview start times using geocoded respondent locations, the time zones in which they were located, and the U.S. Daylight Savings Time schedule. In a final step, fasting times also were adjusted for interviews that stopped prematurely, but resumed later. Data on fasting times (range: 0-23.9 hr) were missing for 141 respondents, the result of recoding implausible values (> 24 hr), missing time zone data, breakoff interviews that resumed before 24 hours elapsed such that the question was not repeated, unrealistic computer timestamps, and answers of “*don’t know*” or “*refused*” to the question.

6.7 Fasted for Nine Hours or More

Variable: FAST_LIP

Respondents who were fasting (≥ 9 hr) and non-fasting (< 9 hr) at the time of blood collection were identified (1,0) based on recommendations of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (National Cholesterol Education Panel 2002).

6.8 Antihyperlipidemic Medication Use

Variable: C_MED2

Use of antihyperlipidemic medications as captured by the Wave IV medication inventory (Tabor et al, 2010) may confound lipid-based estimates of cardiovascular disease risk. Respondents using an antihyperlipidemic medications in the past four weeks with one of the following therapeutic classification codes were therefore assigned a value of 1:

- 358-019-173 HMG-CoA reductase inhibitors
- 358-019-174 Miscellaneous antihyperlipidemic agents
- 358-019-241 Fibrin acid derivatives
- 358-019-252 Bile acid sequestrants
- 358-019-316 Cholesterol absorption inhibitors
- 358-019-317 Antihyperlipidemic combinations

Respondents not using an antihyperlipidemic were assigned a value of 0. The (1,0) classification should be used cautiously in the investigation or control of potential confounding because selection biases often threaten the study of non-randomized medication exposures.

6.9 Joint Classification of Self-Reported History of Hyperlipidemia and Antihyperlipidemic Medication Use

Variable: C_JOINT2

Respondents were jointly classified as having hyperlipidemia if they had self-reported history of hyperlipidemia (H4ID5B=1) or used an antihyperlipidemic medication in the past four weeks (C_MED2=1).

7. References

- Bui TL, Warner CN, Ildefonso J, Pirucki TL, Dewey LM, Maggiore JA. Development of a dried blood collection, transport and testing system for HDL-Cholesterol. *Clin Chem* 2002a; 48(S): A97.
- Bui TL, Warner CN, Ildefonso J, Pirucki TL, Dewey LM, Maggiore JA. Development of a dried blood collection, transport and testing system for total cholesterol. *Clin Chem* 2002b; 48(S): A98.
- Castelli WP, Anderson K, Wilson PWF, Levy D. Lipids and risk of coronary heart disease: the Framingham Study. *Ann Epidemiol* 1992;2:23-28.
- Cornbleet PJ, Gochman N. Incorrect least-squares regression coefficients in method-comparison analysis. *Clin Chem* 1979;25(3):432-8.
- Criqui MH, Golomb BA. Epidemiologic aspects of lipid abnormalities. *Am J Med* 1998;105:48S-57S.
- Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. *Arch Intern Med* 2001;161(11):1413-1419.
- Deal AM, Pate VW, El Roubi S. Paper CC-014. A SAS® Macro for Deming regression, 2011. Available at <http://analytics.ncsu.edu/sesug/2009/CC014.Deal.pdf>.
- Entzel P, Whitsel EA, Richardson A, Tabor J, Hallquist S, Hussey J, Halpern CT, Harris KM. *Add Health Wave IV documentation: Cardiovascular and anthropometric measures*. UNC Chapel Hill: Carolina Population Center, 2009. Available at <http://www.cpc.unc.edu/projects/addhealth/data/guides/Wave%20IV%20cardiovascular%20and%20anthropometric%20documentation%20110209.pdf>.
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18(6):499-502.
- Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. *Am J Cardiol* 1998;81(4A):26B-31B.

Grzeda BR, Bui TL, Warner CN, Pirucki TL, Dewey LM, Maggiore JA. Development of a dried blood collection, transport and testing system for triglycerides. *Clin Chem* 2002; **48**(S):A106.

Harris KM. *Design features of Add Health*. UNC Chapel Hill: Carolina Population Center, 2012. Available at <http://www.cpc.unc.edu/projects/addhealth/data/guides/design%20paper%20W1-IV.pdf>

Harris KM, Halpern CT, Whitsel EA, Hussey JM, Killeya-Jones LA, Tabor J, Dean SC. Cohort Profile: The National Longitudinal Study of Adolescent Health (Add Health). *Int J Epidemiol*; *In press*

Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Usefulness of the total cholesterol to high-density lipoprotein cholesterol ratio in predicting angiographic coronary artery disease in women. *Am J Cardiol* 1991;68:1646-50.

Kinosian B, Glick H, Preiss L, Puder KL. Cholesterol and coronary heart disease: predicting risks in men by changes in levels and ratios. *J Investig Med* 1995;43:443-50.

Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, Levine DM. Serum cholesterol in young men and subsequent cardiovascular disease. *N Engl J Med* 1993;328(5):313-318.

Maggiore JA. *BIOSAFE Safe At Home Cholesterol Profile Blood Collection and Transport System*. US Food and Drug Administration, 510(k) Over-the-Counter Approval, 4/3/02: K012221, 2002.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002;106(25):3143-3421.

Smolen A, Whitsel EA, Tabor J, Killeya-Jones LA, Cuthbertson CC, Hussey J, Halpern CT, Harris KM. *Add Health Wave IV Documentation: Candidate Genes*. UNC Chapel Hill: Carolina Population Center, 2013. Available at http://www.cpc.unc.edu/projects/addhealth/data/guides/DNA_documentation.pdf

Srinivasan SR, Frontini MG, Xu J, Berenson GS. Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study. *Pediatrics* 2006;118(1):201-206.

Stamler J, Daviglius ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. *JAMA* 2000;284(3):311-318.

Tabor J, Whitsel EA. *Add Health Wave IV Documentation: Prescription Medication Use*. UNC Chapel Hill: Carolina Population Center, 2010. Available at http://www.cpc.unc.edu/projects/addhealth/data/guides/medication_documentation.pdf.

Tyrrell SP. *BIOSAFE Safe At Home Test Kit for Monitoring Hemoglobin A1c*. US Food and Drug Administration, 510(k) Over-the-Counter Approval; 11/26/99: K991850.

Whitsel EA, Tabor JW, Nguyen QC, Cuthbertson CC, Wener MH, Potter AJ, Killeya-Jones LA, Harris KM. *Add Health Wave IV Documentation: Measures of Glucose Homeostasis*. UNC Chapel Hill: Carolina Population Center, 2012a. Available at http://www.cpc.unc.edu/projects/addhealth/data/guides/Glucose_HbA1c.pdf.

Whitsel EA, Cuthbertson CC, Tabor JW, Potter AJ, Wener MH, Killeya-Jones LA, Harris KM. *Add Health Wave IV Documentation: Measures of Inflammation and Immune Function*. UNC Chapel Hill: Carolina Population Center, 2012b. Available at <http://www.cpc.unc.edu/projects/addhealth/data/guides/add-health-wave-iv-documentation-measures-of-inflammation-and-immune-function>.